JP2016533344A5 - - Google Patents

Download PDF

Info

Publication number
JP2016533344A5
JP2016533344A5 JP2016517553A JP2016517553A JP2016533344A5 JP 2016533344 A5 JP2016533344 A5 JP 2016533344A5 JP 2016517553 A JP2016517553 A JP 2016517553A JP 2016517553 A JP2016517553 A JP 2016517553A JP 2016533344 A5 JP2016533344 A5 JP 2016533344A5
Authority
JP
Japan
Prior art keywords
composition
use according
protein
cancer
polymer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016517553A
Other languages
English (en)
Japanese (ja)
Other versions
JP7097667B2 (ja
JP2016533344A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/057789 external-priority patent/WO2015048498A2/en
Publication of JP2016533344A publication Critical patent/JP2016533344A/ja
Publication of JP2016533344A5 publication Critical patent/JP2016533344A5/ja
Application granted granted Critical
Publication of JP7097667B2 publication Critical patent/JP7097667B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016517553A 2013-09-27 2014-09-26 無担体生物活性タンパク質ナノ構造体 Expired - Fee Related JP7097667B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361883503P 2013-09-27 2013-09-27
US61/883,503 2013-09-27
PCT/US2014/057789 WO2015048498A2 (en) 2013-09-27 2014-09-26 Carrier-free biologically-active protein nanostructures

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020109309A Division JP7272664B2 (ja) 2013-09-27 2020-06-25 無担体生物活性タンパク質ナノ構造体

Publications (3)

Publication Number Publication Date
JP2016533344A JP2016533344A (ja) 2016-10-27
JP2016533344A5 true JP2016533344A5 (https=) 2017-11-09
JP7097667B2 JP7097667B2 (ja) 2022-07-08

Family

ID=51795741

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2016517553A Expired - Fee Related JP7097667B2 (ja) 2013-09-27 2014-09-26 無担体生物活性タンパク質ナノ構造体
JP2020109309A Active JP7272664B2 (ja) 2013-09-27 2020-06-25 無担体生物活性タンパク質ナノ構造体
JP2023069170A Pending JP2023103260A (ja) 2013-09-27 2023-04-20 無担体生物活性タンパク質ナノ構造体

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2020109309A Active JP7272664B2 (ja) 2013-09-27 2020-06-25 無担体生物活性タンパク質ナノ構造体
JP2023069170A Pending JP2023103260A (ja) 2013-09-27 2023-04-20 無担体生物活性タンパク質ナノ構造体

Country Status (6)

Country Link
US (6) US9603944B2 (https=)
EP (2) EP4043036A1 (https=)
JP (3) JP7097667B2 (https=)
CA (2) CA3191031A1 (https=)
ES (1) ES2904276T3 (https=)
WO (1) WO2015048498A2 (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3191031A1 (en) 2013-09-27 2015-04-02 Massachusetts Institute Of Technology Carrier-free biologically-active protein nanostructures
WO2017027843A1 (en) 2015-08-12 2017-02-16 Massachusetts Institute Of Technology Cell surface coupling of nanoparticles
CN109715196A (zh) * 2016-06-13 2019-05-03 转矩医疗股份有限公司 用于促进免疫细胞功能的组合物和方法
US11123441B2 (en) * 2016-10-04 2021-09-21 The Trustees Of The University Of Pennsylvania Methods and compositions for drug delivery
JP2020530280A (ja) 2017-07-03 2020-10-22 トルク セラピューティクス， インコーポレイテッド 免疫刺激性融合分子およびその使用
WO2019050977A1 (en) * 2017-09-05 2019-03-14 Torque Therapeutics, Inc. REVERSIBLE LINKS AND THEIR USE
CA3074826A1 (en) * 2017-09-05 2019-03-14 Torque Therapeutics, Inc. Therapeutic protein compositions and methods of making and using the same
AU2019339332A1 (en) 2018-09-10 2021-04-08 Torque Therapeutics, Inc. Antigen-specific T lymphocytes and methods of making and using the same
SG11202110810WA (en) * 2019-03-29 2021-10-28 Torque Therapeutics Inc Immunotherapeutic compositions and use thereof
FR3099052B1 (fr) * 2019-07-23 2022-03-25 Univ Franche Comte Structures particulaires à base de nanoparticules d’or, leurs procédés de préparation et leurs utilisations dans le traitement des tumeurs solides
EP3795172A1 (en) 2019-09-20 2021-03-24 Ecole Polytechnique Federale De Lausanne (EPFL) EPFL-TTO Polymer or polycondensate based on peptide, linker and optionally other monomers and method for preparing the same
CN113121670B (zh) * 2020-01-15 2022-11-22 天津键凯科技有限公司 二取代peg化白细胞介素2及其制备方法、应用
CN112125832B (zh) * 2020-08-12 2022-09-20 北京大学 刺突蛋白受体结合结构域纳米凝胶及其制备方法与应用
WO2022165260A1 (en) 2021-01-29 2022-08-04 Iovance Biotherapeutics, Inc. Methods of making modified tumor infiltrating lymphocytes and their use in adoptive cell therapy
CN112891556B (zh) * 2021-02-01 2023-03-03 浙江大学医学院附属第一医院 一种单抗类药物口服纳米凝胶及其制备方法
EP4469065A1 (en) 2022-01-28 2024-12-04 Iovance Biotherapeutics, Inc. Cytokine associated tumor infiltrating lymphocytes compositions and methods
CN115746044A (zh) * 2022-09-27 2023-03-07 大连理工大学 一类含有链中柔性链段和脲键的硅烷偶联剂及其制备方法及其制备方法
EP4605422A2 (en) 2022-10-20 2025-08-27 Repertoire Immune Medicines, Inc. Cd8 t cell targeted il2
EP4634216A1 (en) 2022-12-16 2025-10-22 Repertoire Immune Medicines, Inc. T cell receptors binding hpv-16 epitopes

Family Cites Families (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE147633T1 (de) 1988-10-27 1997-02-15 Univ Minnesota Immunhilfsmittel aus liposome enthaltend lymphokin il -2
JPH03244601A (ja) 1990-02-22 1991-10-31 Masuko Suzuki マンナンと癌細胞分化誘導体の複合体、その製法及び抗癌剤
US5453491A (en) * 1990-09-11 1995-09-26 Kiyoshi Takatsu Murine interleukin-5 receptor
US6197298B1 (en) 1991-04-19 2001-03-06 Tanox, Inc. Modified binding molecules specific for T lymphocytes and their use as in vivo immune modulators in animals
CA2065658A1 (en) 1991-04-19 1992-10-20 Tse-Wen Chang Conjugates of liposomes or microbeads and antibodies specific for t lymphocytes and their use in vivo immune modulators
US5753261A (en) 1993-02-12 1998-05-19 Access Pharmaceuticals, Inc. Lipid-coated condensed-phase microparticle composition
US6180134B1 (en) 1993-03-23 2001-01-30 Sequus Pharmaceuticals, Inc. Enhanced ciruclation effector composition and method
US5464629A (en) 1993-11-16 1995-11-07 Georgetown University Method of forming hydrogel particles having a controlled size using liposomes
EP1167379A3 (en) 1994-07-15 2004-09-08 University Of Iowa Research Foundation Immunomodulatory oligonucleotides
US6056973A (en) 1996-10-11 2000-05-02 Sequus Pharmaceuticals, Inc. Therapeutic liposome composition and method of preparation
IN184589B (https=) 1996-10-16 2000-09-09 Alza Corp
US6120751A (en) 1997-03-21 2000-09-19 Imarx Pharmaceutical Corp. Charged lipids and uses for the same
IN190388B (https=) 1997-10-01 2003-07-26 Biomira Usa Inc
US6787132B1 (en) 1997-12-04 2004-09-07 Yissum Research Development Company Of The Hebrew University Of Jerusalem Combined chemo-immunotherapy with liposomal drugs and cytokines
US6693086B1 (en) 1998-06-25 2004-02-17 National Jewish Medical And Research Center Systemic immune activation method using nucleic acid-lipid complexes
US6319715B1 (en) 2000-04-21 2001-11-20 Cornell Research Foundation, Inc. Method of enhancing the delivery of nucleic acids using silica nanoparticles
US20020151004A1 (en) 2000-07-24 2002-10-17 Roger Craig Delivery vehicles and methods for using the same
WO2002076428A1 (en) 2001-03-26 2002-10-03 Alza Corporation Liposome composition for improved intracellular delivery of a therapeutic agent
US20030235619A1 (en) 2001-12-21 2003-12-25 Christine Allen Polymer-lipid delivery vehicles
JP5014573B2 (ja) 2002-05-09 2012-08-29 オンコサイレオン インコーポレーテッド 脂質ａおよび他の炭水化物リガンド類似体
WO2004032970A2 (en) 2002-10-10 2004-04-22 Samir Mitragotri Carriers attached to blood cells
US8192485B2 (en) * 2002-11-13 2012-06-05 The United States of America, as represented by the Department of Veterens Affairs Reversible hydrogel systems and methods therefor
US7435592B2 (en) 2003-05-13 2008-10-14 Immunovative Therapies, Ltd. Compositions for allogeneic cell therapy
US7402431B2 (en) 2004-03-01 2008-07-22 Immunovative Therapies, Ltd. T-cell therapy formulation
US20040247624A1 (en) 2003-06-05 2004-12-09 Unger Evan Charles Methods of making pharmaceutical formulations for the delivery of drugs having low aqueous solubility
US7223544B2 (en) 2003-06-27 2007-05-29 Cornell Research Foundation, Inc. Nucleic acid-engineered materials
US20050042298A1 (en) 2003-08-20 2005-02-24 Pardridge William M. Immunonanoparticles
EP1550458A1 (en) 2003-12-23 2005-07-06 Vectron Therapeutics AG Synergistic liposomal adjuvants
ES2367027T3 (es) 2004-02-27 2011-10-27 Inserm (Institut National De La Santé Et De La Recherche Medicale) Sitio de unión de la il-15 para il-15ralfa y mutantes específicos de il-15 que tienen actividad agonista/antagonista.
US20050266067A1 (en) 2004-03-02 2005-12-01 Shiladitya Sengupta Nanocell drug delivery system
WO2006080951A2 (en) 2004-07-01 2006-08-03 Yale University Targeted and high density drug loaded polymeric materials
TW200616604A (en) 2004-08-26 2006-06-01 Nicholas Piramal India Ltd Nitric oxide releasing prodrugs containing bio-cleavable linker
DE102004054536A1 (de) 2004-11-06 2006-05-11 Capsulution Nanoscience Ag Multimodal veränderte Zellen als zellulare Darreichungsformen für aktive Substanzen und als diagnostische Zellpartikel
US8246995B2 (en) 2005-05-10 2012-08-21 The Board Of Trustees Of The Leland Stanford Junior University Hydrophobic nanotubes and nanoparticles as transporters for the delivery of drugs into cells
EP3263581B2 (en) 2005-05-17 2025-07-09 University of Connecticut Compositions and methods for immunomodulation in an organism
US20070148246A1 (en) 2005-08-11 2007-06-28 Dan Luo Nucleic Acid-Based Matrixes
WO2007022152A2 (en) 2005-08-15 2007-02-22 The Research Foundation Of State University Of New York Lipid nano particulates containing antigens as cancer vaccines
US20080267876A1 (en) 2005-09-20 2008-10-30 Yissum Research Development Company Nanoparticles for Targeted Delivery of Active Agent
JP2007131568A (ja) * 2005-11-09 2007-05-31 Nippon Seiyaku Kogyo Kk 免疫賦活剤及びこれを含有する免疫賦活性飲食物
KR101152557B1 (ko) 2005-12-12 2012-09-07 에이씨 이뮨 에스.에이. 치료 백신
CA2601803A1 (en) 2006-01-13 2007-07-19 Riken Preventive or therapeutic agent and method for immune disease
CA2643826A1 (en) 2006-02-27 2008-06-12 Paul A. Wender Compositions and methods for transport of molecules with enhanced release properties across biological barriers
AU2007271398B2 (en) 2006-07-06 2013-06-20 Merck Patent Gmbh Compositions and methods for enhancing the efficacy of IL-2 mediated immune responses
WO2008057163A2 (en) * 2006-10-09 2008-05-15 Carnegie Mellon University Preparation of functional gel particles with a dual crosslink network
US20110177156A1 (en) 2007-11-14 2011-07-21 Szoka Jr Francis C Sterol-Modified Amphiphilic Lipids
JP2009149526A (ja) 2007-12-18 2009-07-09 Tokyo Medical & Dental Univ サイトカイン−ナノゲル複合体を含む皮下注射又は筋肉内注射徐放製剤
WO2009134866A2 (en) 2008-04-29 2009-11-05 The Brigham And Women's Hospital, Inc. Cell membrane engineering
US9283184B2 (en) 2008-11-24 2016-03-15 Massachusetts Institute Of Technology Methods and compositions for localized agent delivery
US8765171B2 (en) 2009-03-09 2014-07-01 The Regents Of The University Of California Methods and compositions for liposomal formulation of antigens and uses thereof
SG174287A1 (en) 2009-03-09 2011-10-28 Univ California Single protein nanocapsules for protein delivery with long-term effect
BRPI1012036A2 (pt) 2009-05-27 2017-10-10 Selecta Biosciences Inc nanocarreadores que possuem componentes com diferentes taxas de liberação
US20100324124A1 (en) 2009-06-17 2010-12-23 Massachusetts Institute Of Technology Compositions and methods relating to DNA-based particles
US20100323018A1 (en) 2009-06-17 2010-12-23 Massachusetts Institute Of Technology Branched DNA/RNA monomers and uses thereof
PT2501413T (pt) 2009-11-18 2019-07-10 Nektar Therapeutics Formas de sal de ácido de conjugados de polímero-fármaco
US20110229556A1 (en) 2010-03-19 2011-09-22 Massachusetts Institute Of Technology Lipid-coated polymer particles for immune stimulation
US9149432B2 (en) 2010-03-19 2015-10-06 Massachusetts Institute Of Technology Lipid vesicle compositions and methods of use
CN102917690B (zh) 2010-03-19 2016-08-24 麻省理工学院 脂质囊泡组合物和使用方法
WO2012024396A2 (en) 2010-08-17 2012-02-23 Rutgers, The State University Of New Jersey Compositions and methods for delivering nucleic acid molecules and treating cancer
EP2616103A1 (en) 2010-09-16 2013-07-24 The University of North Carolina At Chapel Hill Asymmetric bifunctional silyl monomers and particles thereof as prodrugs and delivery vehicles for pharmaceutical, chemical and biological agents
US8507222B2 (en) 2010-09-21 2013-08-13 Altor Bioscience Corporation Multimeric IL-15 soluble fusion molecules and methods of making and using same
WO2012112689A1 (en) 2011-02-15 2012-08-23 The University Of North Carolina At Chapel Hill Nanoparticle, liposomes, polymers, agents and proteins modified with reversible linkers
US20140037748A1 (en) 2011-04-15 2014-02-06 The Regents Of The University Of California Redox responsive polymeric nanocapsules for protein delivery
WO2013033430A1 (en) * 2011-09-02 2013-03-07 Wake Forest School Of Medicine Targeted delivery and prodrug designs for platinum-acridine anti-cancer compounds and methods thereof
JP2013173689A (ja) 2012-02-24 2013-09-05 Univ Of Tsukuba 高分子化ニトロキシドラジカル化合物と非ステロイド性抗炎症薬の複合体
US20130337471A1 (en) 2012-06-14 2013-12-19 Emory University Cell identification with nanoparticles, compositions and methods related thereto
US9149535B2 (en) * 2012-06-28 2015-10-06 University Of South Carolina Polymers and the preparation of nanogel drug cocktails
FR3004106B1 (fr) 2013-04-05 2016-08-05 Oreal Composition contenant des particules composites filtrant les radiations uv de taille moyenne superieure a 0,1μm et des particules d'aerogel de silice hydrophobes
CA2953287A1 (en) 2013-06-19 2014-12-24 Massachusetts Institute Of Technology In vivo targeting of cells with ligand-conjugated particles
CA3191031A1 (en) 2013-09-27 2015-04-02 Massachusetts Institute Of Technology Carrier-free biologically-active protein nanostructures
WO2017027843A1 (en) * 2015-08-12 2017-02-16 Massachusetts Institute Of Technology Cell surface coupling of nanoparticles
CN109715196A (zh) 2016-06-13 2019-05-03 转矩医疗股份有限公司 用于促进免疫细胞功能的组合物和方法
US10933660B2 (en) 2017-02-01 2021-03-02 Hewlett-Packard Development Company, L.P. Output tension zones

Similar Documents

Publication Publication Date Title
JP2016533344A5 (https=)
JP6929572B2 (ja) 免疫療法のための調節粒子
US20250222177A1 (en) Modified alginates for anti-fibrotic materials and applications
Liu et al. Injectable supramolecular hydrogel for locoregional immune checkpoint blockade and enhanced cancer chemo-immunotherapy
Wang et al. Biomaterial-assisted targeted modulation of immune cells in cancer treatment
Chang et al. Supramolecular immunotherapy of cancer based on the self‐assembling peptide design
Wongpinyochit et al. PEGylated silk nanoparticles for anticancer drug delivery
Patra et al. Alginate-chitosan biodegradable and biocompatible based hydrogel for breast cancer immunotherapy and diagnosis: a comprehensive review
Suarez et al. Tunable protein release from acetalated dextran microparticles: a platform for delivery of protein therapeutics to the heart post-MI
US20200253192A1 (en) Zwitterionic microgels, their assemblies and related formulations, and methods for their use
Bobbala et al. Novel injectable pentablock copolymer based thermoresponsive hydrogels for sustained release vaccines
EP2590679B1 (en) Immunomodulatory protein constructs with a helical polymeric backbone
AU2017375793B2 (en) Microparticles and nanoparticles having negative surface charges
CN103910802B (zh) 一种促进树突细胞摄取抗原肽的多肽、促进树突细胞摄取抗原肽的纳米颗粒及其应用
Lanis et al. Hydrogels in the Immune Context: In Vivo Applications for Modulating Immune Responses in Cancer Therapy
Nguyen et al. Strategies to Design and Optimize Artificial Antigen‐Presenting Cells for T Cell Expansion in Cancer Immunotherapy
US12171810B2 (en) Angiogenesis promoter and therapeutic method
US20140005199A1 (en) Implant for the controlled release of pharmaceutically active agents
Xiao et al. Amplifying antitumor T cell immunity with versatile drug delivery systems for personalized cancer immunotherapy
Zhang et al. Photoimmunological hydrogel vaccine creates a supportive immune niche to promote antigen cross-presentation cascade and cancer-immunity cycle progression
Dhayani et al. An Amphiphilic Double‐Brush Polymer Hydrogel for Sustained Release of Small Molecules and Biologics: Insulin Delivering‐Hydrogel to Control Hyperglycemia
Amiji et al. Systemic Drug Delivery Strategies: Volume 2 of Delivery Strategies and Engineering Technologies in Cancer Immunotherapy
Rhodes POLYMERIC PARTICLE-BASED DRUG DELIVERY PLATFORMS FOR IMMUNE MODULATION
Hou et al. Validation of a dual role of methotrexate-based chitosan nanoparticles in vivo
CN116726161A (zh) 一种负载抗原多肽的白蛋白递送系统及其制备方法和应用